Rituxan Adds Third NHL Indication In 2006

The Genentech/Biogen Idec oncologic, first approved in 1997, is now also approved for first-line with CVP and ongoing treatment of stable disease.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Pink Sheet